Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

557 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-21

Study Completion Date

2007-09-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

NCT00231790

Urinary Incontinence

COMPLETED PHASE2

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

NCT00335660

Overactive Bladder Syndrome

TERMINATED PHASE2

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

NCT00196404

Urinary Incontinence

COMPLETED PHASE2

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00662909

Urinary Bladder, Overactive

COMPLETED PHASE3

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636

Overactive Bladder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Incontinence Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0594

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with predominantly urge incontinence overactive bladder episodes
* Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards

Exclusion Criteria

* History of Diabetes insipidus, uncontrolled hyperglycemia or hypercalcemia
* Lower urinary tract symptoms associated with benign prostatic hypertrophy
* Active or current Urinary Tract Infections (UTIs)
* Surgery to correct prolapsed uterus or stress incontinence

Minimum Eligible Age

40 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No